# A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

> **NCT03625778** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 51 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** MEDI0382
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03625778
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-14
- **Primary completion:** 2019-08-25
- **Final completion:** 2019-08-25
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2021-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03625778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03625778, "A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03625778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*